Cost-effectiveness of peginterferon alfa-2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan

Journal of Gastroenterology and Hepatology (Australia)

Volumn 22, Issue 9, 2007, Pages 1494-1499

  Sullivan, Sean D ^a   Veenstra, David L ^a   Chen, Pei Jer ^b   Chang, Ting Tsung ^c   Chuang, Wan Long ^d   Tsai, Chiaming ^e   Patel, Kavita ^f  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e Roche Products Ltd   (Taiwan)

^f HOFFMANN LA ROCHE INC   (United States)

Author keywords

Cost effectiveness; Lamivudine; Peginterferon alfa 2a; Viral hepatitis

Indexed keywords

HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2A;

ARTICLE; ASIAN; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HEALTH INSURANCE; HEPATITIS B; LIFE EXPECTANCY; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SENSITIVITY ANALYSIS; SIMULATION; TAIWAN; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84984563844     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2006.04539.x     Document Type: Article

References (30)

1. Mohamed R, Desmond P, Suh DJ et al. Practical difficulties in the management if hepatitis B in the Asia-Pacific region. J. Gastroenterol. Hepatol. 2004 19 : 958 69.
2. Liaw YF, Leung N, Guan R, Lau GK, Merican I, Asian-Pacific Consensus Working Parties on Hepatitis B. Asian-Pacific consensus statement on the management of chronic hepatitis B: an update. J. Gastroenterol. Hepatol. 2003 18 : 239 45.
3. Liaw YF, Sung JJ, Chow WC et al., Cirrhosis Asian Lamivudine Multicentre Study Group. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 2004 351 : 1521 31.
4. Chen CJ et al. Epidemiology characteristics and risk factors of hepatocellular carcinoma. Gastroenterol. Hepatol. 1997 12 (Suppl. 294 308.
5. The Taiwan Department of Health Statistics Center. Main Causes of Death in Taiwan for the Year of 2003. [Cited 15 Nov 2004]. Available from URL: http://www.doh.gov.tw/statistic/index.htm
6. Taiwan Bureau of National Health Insurance. Medical Care of Liver Disease. 11 November 11. Available from URL: http://www.nhi.gov.tw/06inquire/ query8_detail.asp?News_ID=380.
7. Lai CL, Chien RN, Leung NW et al. A one year trial of lamivudine for CHB. N. Engl. J. Med. 1998 339 : 61 8.
8. Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. HBeAg seroconversion after lamivudine therapy is not durable in patients with CHB in Korea. Hepatology 2000 32 : 803 6.
9. Lok AS, McMahon BJ. Practice guidelines committee, American Association for the Study of Liver Diseases. Chronic hepatitis B. Hepatology 2001 34 : 1225 41.
10. EASL Jury. EASL international consensus conference on hepatitis B. J. Hepatol. 2003 38 : 533 40.
11. Lau GK, Piratvisuth T, Luo KX et al., Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 2005 352 : 2682 95.
12. Crowley SJ, Tognarini D, Desmond PV, Lees M. Cost-effectiveness analysis of lamivudine for the treatment of chronic hepatitis B. Pharmacoeconomics 2000 17 : 409 27.
13. Pwu RF, Chan KA. Cost effectiveness analysis of interferon α therapy in the treatment of chronic hepatitis B in Taiwan. J. Formos. Med. Assoc. 2002 101 : 632 41.
14. The 2002 Abridged Life Table in Taiwan-Fuchien Area from Ministry of the Interior, ROC. [Cited 15 Nov 2004]. Available from URL: http://www.moi.gov.tw/ stat/Life/tc915200.htm
15. van Nunen AB, Hansen BE, Suh DJ et al. Durability of HBeAg seroconversion following antiviral therapy for CHB: relation to type of therapy and pre-treatment serum HBV DNA and ALT. Gut 2003 52 : 420 4.
16. Wang CC, Kowdley KV. Built to last? Durability of lamivudine-induced seroconversion in patients with chronic hepatitis B. Gastroenterology 2004 126 : 1917 19.
17. Lok AS, Lai CL, Wu PC, Leung EK, Lam TS. Spontaneous HBeAg to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology 1987 92 : 1839 43.
18. Taiwan Bureau of National Health Insurance. Fee Schedule for Medical Service and Reference List for Drugs. [Cited 6 Dec 2004]. Available from URL: http://www.nhi.gov.tw/06inquire/query1.asp
19. Wang JD. Estimation of Life Years Lost and Financial Burden of Major Cancer in Taiwan. Taipei : Australia-Taiwan Clinical Trial Symposium, 20-21 November 2004.
20. Chang Gung Memorial Hospital-Kaohsiung. Liver Transplant. [Cited 15 Nov 2004]. Available from URL: http://www.clchen.org.tw
21. Wong JB, Koff RS, Tine F, Pauker SG. Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann. Intern. Med. 1995 122 : 664 75.
22. Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann. Intern. Med. 1997 127 : 855 65.
23. Taiwan Department of Statistics, Ministry of Economic Affairs, ROC. GNP per capita of main countries. [Cited 6 Dec 2004]. Available from URL. http://win.dgbas.gov.tw/dgbas03/bs8/world/pergdp.htm
24. Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988 8 : 493 6.
25. Liaw YF, Tai DI, Chu CM et al. Early detection of HCC in patients with CHB. A prospective study. Gastroenterology 1986 90 : 263 7.
26. Liaw YF, Lin DY, Chen TJ, Chu CM. Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Liver 1989 9 : 235 41.
27. Lau DT, Everhart J, Kleiner DE et al. Long-term follow up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 1997 113 : 1660 7.
28. The Organ Transplanation Registry in Taiwan. Taipei : The Transplant Society of Taiwan, 20 October 2004.
29. Chen CL, Fan ST, Lee SG, Makuuchi M, Tanaka K. Living-donor liver transplantation: 12 years of experience in Asia. Transplantation 2003 75 : 6 11.
30. Taiwan Bureau of National Health Insurance. Medical Care of Liver Disease (Taiwanese). [Cited 30 Jun 2004]. Available from URL: http://www.nhi.gov.tw/ 07information/news_detail.asp?News_ID=422.